Papp L Roy & Associates lowered its stake in PAREXEL International Co. (NASDAQ:PRXL) by 75.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,950 shares of the medical research company’s stock after selling 21,382 shares during the quarter. Papp L Roy & Associates’ holdings in PAREXEL International were worth $612,000 at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of the stock. FDx Advisors Inc. boosted its holdings in PAREXEL International by 26.1% in the third quarter. FDx Advisors Inc. now owns 3,176 shares of the medical research company’s stock worth $280,000 after purchasing an additional 658 shares during the last quarter. Jennison Associates LLC bought a new position in PAREXEL International in the third quarter worth approximately $448,000. Harvest Management LLC raised its position in PAREXEL International by 100.0% in the third quarter. Harvest Management LLC now owns 20,000 shares of the medical research company’s stock worth $1,762,000 after acquiring an additional 10,000 shares during the period. IndexIQ Advisors LLC bought a new position in PAREXEL International in the third quarter worth approximately $8,986,000. Finally, Gabelli Funds LLC raised its position in PAREXEL International by 373.7% in the third quarter. Gabelli Funds LLC now owns 320,992 shares of the medical research company’s stock worth $28,273,000 after acquiring an additional 253,224 shares during the period. Institutional investors own 87.45% of the company’s stock.
Several research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of PAREXEL International from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research report on Thursday, August 31st. BidaskClub downgraded shares of PAREXEL International from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. PAREXEL International presently has a consensus rating of “Hold” and an average price target of $78.68.
Shares of PAREXEL International Co. (NASDAQ:PRXL) traded down $0.02 during mid-day trading on Monday, hitting $88.08. 7,021,100 shares of the stock traded hands, compared to its average volume of 1,041,144. PAREXEL International Co. has a 12-month low of $51.16 and a 12-month high of $88.10. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.45 and a current ratio of 1.45.
PAREXEL International (NASDAQ:PRXL) last announced its quarterly earnings data on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.94 by $0.08. The firm had revenue of $557.20 million for the quarter, compared to the consensus estimate of $537.59 million. PAREXEL International had a net margin of 4.62% and a return on equity of 19.95%. During the same period last year, the firm earned $0.94 EPS.
About PAREXEL International
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Co. (NASDAQ:PRXL).
Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.